keyword
MENU ▼
Read by QxMD icon Read
search

neo-adjuvant chemotherapy

keyword
https://www.readbyqxmd.com/read/28912926/a-rare-case-of-atrial-metastasis-from-a-rectal-adenocarcinoma
#1
Srinivas S Ayyala, Dawnette M Urcuyo, Paul T Kannarkatt, James E Kovacs, Nicole J Terrigno
Colorectal cancers typically metastasize to the lymph nodes, liver or lungs. Metastasis to the heart is rare and although a few cases of cardiac metastases from colon cancer are described in the literature, cases of metastatic rectal cancer to the heart are far fewer. A 69-year-old woman with a history of rectal adenocarcinoma treated with neo-adjuvant chemotherapy and radiation, followed by resection and adjuvant chemotherapy, presented with increasing dyspnea on exertion and lower extremity edema 5 years after oncology follow-up...
October 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28910957/-effects-of-cell-cycle-regulatory-genes-on-breast-cancer-neo-adjuvant-chemotherapy-by-m-fish
#2
C Y Li, W Su, S Zhang, Y H Hu, J J Liu, J Zhang
Objective: The dysregulation of cell cycle could influence cell proliferation, differentiation and response to medicine. The purpose of this study is to explore the correlation between cell cycle regulatory genes and breast cancer neo-adjuvant chemotherapy (NAC) in patients with local advanced breast cancer, and thus to find some predictors of NAC to provide guidance for clinical treatment. Methods: Ninety five cases of local advanced breast cancer were collected, which were treated with NAC of TAC (Taxanes/Anthracycline/Cyclophosphamide) regimen...
September 12, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28905005/management-of-gastric-cancer-in-indian-population
#3
REVIEW
Mohammed Ibrahim, Kissan Gilbert
Adenocarcinoma stands the most common malignancies in the gastric carcinomas and holds a significant mortality and morbidity rates annually, due to the early vague symptoms among the population and hence the delayed presentation at advanced stages of cancer. In India the screening programs for gastric cancer has been a setback due to various logistics reasons and the data available from reporting is also not content. Our study is a review article featuring the management of gastric cancer in the Indian population...
2017: Translational Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28890993/chemotherapy-in-nets-when-and-how
#4
REVIEW
Anna Angelousi, Gregory Kaltsas, Anna Koumarianou, Martin O Weickert, Ashley Grossman
The majority of neuroendocrine tumours (NETs) are well-differentiated tumours that follow an indolent course, in contrast to a minority of poorly differentiated neuroendocrine carcinomas (NECs) which exhibit an aggressive course and assocaited with an overall short survival. Although surgery is the only curative treatment for NETs it is not always feasible,necessitating the application of other therapies including chemotherapy. Streptozotocin (STZ)-based regimens have long been used for advanced or metastatic well-to-moderately differentiated (G1-G2) NETs, especially those originating from the pancreas (pNETs)...
September 11, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28876635/the-surgical-management-of-central-breast-tumours-at-a-specialist-breast-unit-in-johannesburg-south-africa
#5
L Van Schalkwyk, C A Benn, K Bergstrom
BACKGROUND: Central breast tumours are defined as tumours in the retroareolar area, or within 1.5-2.0 cm from the areolar edge. In the past, breast conservation therapy (BCT) for central breast tumours was considered controversial due to concerns regarding oncologic safety and cosmesis. Recent evidence does however suggest that oncoplastic techniques offer a cosmetically acceptable and safe alternative to mastectomy in these tumours. METHOD: Patients with central breast tumours (invasive and in situ) were identified from a breast cancer database of 431 patients who presented to the Netcare Breast Care Centre in Johannesburg over a one-year period (June 2015-June 2016)...
June 2017: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie
https://www.readbyqxmd.com/read/28876634/clinical-vs-pathological-staging-of-breast-cancer-can-our-hands-compete-with-the-microscope
#6
L Van Schalkwyk, C A Benn, K Bergstrom
BACKGROUND: Tumour size and axillary nodal status are important predictors of prognosis in breast cancer. The clinical examination of the breast is an essential component of preoperative TNM staging, but the accuracy of this method of assessment has been called into question, especially in the determination of axillary nodal status. METHOD: Data were obtained from a database of breast cancer patients presenting to the Netcare Breast Care Centre in Johannesburg between June 2015 and June 2016...
June 2017: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie
https://www.readbyqxmd.com/read/28860439/-comparison-between-primary-debulking-surgery-and-neo-adjuvant-chemotherapy-followed-by-interval-debulking-surgery-for-patients-with-stage-iii-iv-ovarian-cancer
#7
Kanoko Shimoji, Kimihiko Ito, Lena Tashima, Tomohiko Tsuruta, Mio Nakagawa, Yoshinori Kagawa, Yutaka Takeda, Takashi Iwata, Taro Yagi, Chihiro Odani, Hitomi Ono, Rieko Okubo, Mayako Goto, Kensuke Hori
The current standard treatment for advanced ovarian cancer is primary debulking surgery(PDS). We may expect a good prognosis if complete debulking(no visible residual tumor)is possible. However, if complete surgery is not possible owing to the location of the tumor or poor performance status, neo-adjuvant chemotherapy(NAC)could be an alternative option. Interval debulking surgery(IDS)can be planned after NAC to try and achieve complete debulking surgery. We reviewed stage III and IV epithelial ovarian cancers treated at Kansai Rosai Hospital between January 2012 and January 2016...
August 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28841916/neoadjuvant-chemotherapy-versus-surgery-first-for-resectable-pancreatic-cancer-norwegian-pancreatic-cancer-trial-1-norpact-1-study-protocol-for-a-national-multicentre-randomized-controlled-trial
#8
Knut Jørgen Labori, Kristoffer Lassen, Dag Hoem, Jon Erik Grønbech, Jon Arne Søreide, Kim Mortensen, Rune Smaaland, Halfdan Sorbye, Caroline Verbeke, Svein Dueland
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological treatment. Thus, completion of multimodality treatment (surgical resection and (neo)adjuvant chemotherapy) to all patients and early treatment of micrometastatic disease is the ideal goal. NorPACT-1 aims to test the hypothesis that overall mortality at one year after allocation of treatment can be reduced with neoadjuvant chemotherapy in surgically treated patients with resectable pancreatic cancer...
August 25, 2017: BMC Surgery
https://www.readbyqxmd.com/read/28833787/efficacy-of-a-global-supportive-skin-care-programme-with-hydrotherapy-after-non-metastatic-breast-cancer-treatment-a%C3%A2-randomised-controlled-study
#9
F Dalenc, V Ribet, A B Rossi, J Guyonnaud, C Bernard-Marty, B de Lafontan, S Salas, A-L Ranc Royo, C Sarda, N Levasseur, C Massabeau, J-M Levecq, P Dulguerova, D Guerrero, V Sibaud
This study investigated the efficacy of post-treatment hydrotherapy as supportive care for management of persistent/long-lasting dermatologic adverse events (dAEs) induced in breast cancer survivors by adjuvant therapy, and its impact on quality of life (QoL). Patients in complete remission after standardised (neo)adjuvant chemotherapy, surgery and radiotherapy combination treatment for infiltrating HR+/HER2-breast carcinoma were enrolled in this randomised, multicentre controlled study 1-5 weeks after completing radiotherapy...
August 22, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28816143/radiation-therapy-versus-no-radiation-therapy-to-the-neo-breast-following-skin-sparing-mastectomy-and-immediate-autologous-free-flap-reconstruction-for-breast-cancer-patient-reported-and-surgical-outcomes-at-1-year-a-mastectomy-reconstruction-outcomes-consortium
#10
MULTICENTER STUDY
Andrew L Cooke, Julian Diaz-Abele, Tom Hayakawa, Ed Buchel, Kimberly Dalke, Pascal Lambert
PURPOSE: To determine whether adjuvant radiation therapy (RT) is associated with adverse patient-reported outcomes and surgical complications 1 year after skin-sparing mastectomy and immediate autologous free flap reconstruction for breast cancer. METHODS AND MATERIALS: We compared 24 domains of patient-reported outcome measures 1 year after autologous reconstruction between patients who received adjuvant RT and those who did not. A total of 125 patients who underwent surgery between 2012 and 2015 at our institution were included from the Mastectomy Reconstruction Outcomes Consortium study database...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28806981/understanding-the-potentiality-of-accelerator-based-boron-neutron-capture-therapy-for-osteosarcoma-dosimetry-assessment-based-on-the-reported-clinical-experience
#11
Silva Bortolussi, Ian Postuma, Nicoletta Protti, Lucas Provenzano, Cinzia Ferrari, Laura Cansolino, Paolo Dionigi, Olimpio Galasso, Giorgio Gasparini, Saverio Altieri, Shin-Ichi Miyatake, Sara J González
BACKGROUND: Osteosarcoma is the most frequent primary malignant bone tumour, and its incidence is higher in children and adolescents, for whom it represents more than 10% of solid cancers. Despite the introduction of adjuvant and neo-adjuvant chemotherapy that markedly increased the success rate in the treatment, aggressive surgery is still needed and a considerable percentage of patients do not survive due to recurrences or early metastases. Boron Neutron Capture Therapy (BNCT), an experimental radiotherapy, was investigated as a treatment that could allow a less aggressive surgery by killing infiltrated tumour cells in the surrounding healthy tissues...
August 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28800861/ipatasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line-therapy-for-metastatic-triple-negative-breast-cancer-lotus-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#12
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga
BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium...
August 8, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28764688/developing-a-patient-decision-aid-for-the-treatment-of-women-with-early-stage-breast-cancer-the-struggle-between-simplicity-and-complexity
#13
W Savelberg, T van der Weijden, L Boersma, M Smidt, C Willekens, A Moser
BACKGROUND: A patient decision aid (PtDA) can support shared decision making (SDM) in preference-sensitive care, with more than one clinically applicable treatment option. The development of a PtDA is a complex process, involving several steps, such as designing, developing and testing the draft with all the stakeholders, known as alpha testing. This is followed by testing in 'real life' situations, known as beta testing, and then finalising the definite version. Our aim was developing and alpha testing a PtDA for primary treatment of early stage breast cancer, ensuring that the tool is considered relevant, valid and feasible by patients and professionals...
August 1, 2017: BMC Medical Informatics and Decision Making
https://www.readbyqxmd.com/read/28761726/phase-i-study-of-neoadjuvant-chemotherapy-with-s-1-and-oxaliplatin-for-locally-advanced-gastric-cancer-neo-g-sox-pi
#14
Hironaga Satake, Akira Miki, Masato Kondo, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Hisateru Yasui, Yukihiro Imai, Chihiro Ichikawa, Kenta Murotani, Hiroki Hashida, Hiroyuki Kobayashi, Masahito Kotaka, Takeshi Kato, Satoshi Kaihara, Akihito Tsuji
BACKGROUND: The prognosis of locally advanced gastric cancer, such as clinical T4 disease, bulky nodal involvement, type 4 and large type 3 gastric cancer, remains unsatisfactory, even with D2 gastrectomy followed by adjuvant chemotherapy. One promising approach is neoadjuvant chemotherapy. Combination chemotherapy with S-1 and oxaliplatin (SOX) is recognised as a potentially promising regimen for gastric cancer. However, the use of neoadjuvant chemotherapy consisting of SOX for locally advanced gastric cancer has not been reported...
2017: ESMO Open
https://www.readbyqxmd.com/read/28741395/predictive-value-of-the-age-adjusted-charlston-co-morbidity-index-on-peri-operative-complications-adjuvant-chemotherapy-usage-and-survival-in-patients-undergoing-debulking-surgery-after-neo-adjuvant-chemotherapy-for-advanced-epithelial-ovarian-cancer
#15
Andrew Phillips, Kavita Singh, Rachel Pounds, Sudha Sundar, Sean Kehoe, James Nevin, Ahmed Elattar, Janos Balega
The aim of this study was to determine whether the age-adjusted Charlston co-morbidity index (ACCI) can predict post-operative complications, adjuvant chemotherapy usage and overall survival (OS) in patients with advanced epithelial ovarian cancer (AOC) treated with neoadjuvant chemotherapy (NACT). A review was performed of all cytoreductive surgeries performed between 16/8/07-3/2/14 for AOC at a UK Cancer Centre. All surgeries were stratified by ACCI into three groups: Low (0-1), Intermediate (2-3) and High (≥4)...
July 25, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28721098/patient-selection-for-cytoreductive-surgery-and-hipec-for-the-treatment-of-peritoneal-metastases-from-colorectal-cancer
#16
REVIEW
Geert A Simkens, Koen P Rovers, Simon W Nienhuijs, Ignace H de Hingh
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28718942/the-shift-toward-neo-adjuvant-chemotherapy-and-interval-debulking-surgery-for-management-of-advanced-ovarian-and-related-cancers-in-a-population-based-setting-impact-on-clinical-outcomes
#17
James L Nicklin, Shaun McGrath, Lee Tripcony, Andrea Garrett, Russell Land, Amy Tang, Lewis Perrin, Naven Chetty, Nisha Jagasia, Alex J Crandon, Marcelo Nascimento, Graeme Walker, Karen Sanday, Andreas Obermair
OBJECTIVES: The aim of this study was to determine the proportion of patients with advanced ovarian and related cancers (EOC+RC), treated with neoadjuvant chemotherapy and interval debulking surgery (NACT - IDS), and to determine if there was any relationship with optimal cytoreduction rates and overall survival (OS) in a state-wide gynaecologic oncology service over time. METHODS: A retrospective review was undertaken using a population-based database of patients with stages 3 and 4 EOC+RC treated from 1982 till 2013 at the Queensland Centre for Gynaecological Cancer (QCGC)...
July 18, 2017: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28717754/surgical-management-of-breast-cancer-in-africa-a-continent-wide-review-of-intervention-practices-barriers-to-care-and-adjuvant-therapy
#18
REVIEW
Stephanie A Sutter, Aaron Slinker, Deo Darius Balumuka, Katrina B Mitchell
Breast cancer has emerged as a leading cancer among women in Africa, necessitating improved understanding of its management across the continent. Although previous studies have described regional trends in therapy, this review aims to summarize continent-wide management and focus specifically on surgical interventions. Current literature shows that the rates of surgery, chemotherapy, and radiation therapy vary across different countries and institutions, indicating the need for greater use of standardized cancer treatment guidelines...
April 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28717136/association-of-plasma-and-urinary-mutant-dna-with-clinical-outcomes-in-muscle-invasive-bladder-cancer
#19
K M Patel, K E van der Vos, C G Smith, F Mouliere, D Tsui, J Morris, D Chandrananda, F Marass, D van den Broek, D E Neal, V J Gnanapragasam, T Forshew, B W van Rhijn, C E Massie, N Rosenfeld, M S van der Heijden
Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, from 17 patients undergoing NAC. We assessed single nucleotide variants and copy number alterations in mutDNA using Tagged-Amplicon- and shallow Whole Genome- Sequencing...
July 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28711750/web-based-tailored-psycho-education-for-breast-cancer-patients-at-the-onset-of-the-survivorship-phase-a-multicenter-randomized-controlled-trial
#20
Jolien M Admiraal, Annette W G van der Velden, Jenske I Geerling, Johannes G M Burgerhof, Grietje Bouma, Annemiek M E Walenkamp, Elisabeth G E de Vries, Carolien P Schröder, Anna K L Reyners
CONTEXT: Many breast cancer patients have unmet informational and psychosocial needs after treatment completion. A psycho-educational intervention may be well-suited to support these patients. OBJECTIVES: The purpose of this multicenter randomized controlled trial was to examine the effectiveness of a web-based tailored psycho-educational program (ENCOURAGE) for breast cancer patients which aims to empower patients to take control over prevailing problems. METHODS: Female breast cancer patients from two hospitals in the Netherlands who recently completed (neo-)adjuvant chemotherapy were randomly assigned to standard care or 12-week access to the ENCOURAGE program providing fully automated information, problem-solving strategies, resources and services for reported problems...
July 12, 2017: Journal of Pain and Symptom Management
keyword
keyword
109145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"